Codexis to Produce 50g siRNA with ECO Synthesis Platform for Preclinical Cardiovascular Program
Codexis will manufacture 50 grams of siRNA for a partner’s preclinical cardiovascular candidate using its proprietary ECO Synthesis Manufacturing Platform, marking the platform’s first large-volume engagement beyond research-scale production. The agreement establishes a potential pathway for further scale-up toward commercial-scale RNA therapeutic manufacturing.
1. Agreement Overview
Codexis has entered into an agreement to produce 50 grams of small interfering RNA for an innovator pharmaceutical partner’s preclinical program targeting a cardiovascular indication, demonstrating the ability to supply meaningful quantities beyond early-stage research.
2. ECO Synthesis Capabilities
The proprietary ECO Synthesis Manufacturing Platform is designed for efficient, scalable and high-fidelity production of complex siRNA therapeutics, addressing rising demands in yield, consistency and resource efficiency as RNA therapies expand into larger indication areas.
3. Growth and Scale-up Potential
This engagement serves as an important entry point for Codexis into higher-volume opportunities, establishing a foundation for potential commercial-scale applications and underscoring the platform’s role in the company’s expansion strategy.